Bausch & Lomb vs. Somerset Therapeutics: Ophthalmic Patent Dispute Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bausch & Lomb, Inc. v. Somerset Therapeutics, LLC |
| Case Number | 3:25-cv-03395 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Apr 2025 – Jan 2026 259 days |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Somerset’s generic brimonidine tartrate ophthalmic solution at 0.025% |
Introduction
In a closely watched pharmaceutical patent dispute, Bausch & Lomb, Inc. and Somerset Therapeutics, LLC reached a stipulated dismissal without prejudice in the U.S. District Court for the District of New Jersey, closing case No. 3:25-cv-03395 on January 12, 2026—just 259 days after filing. The action centered on four patents protecting Lumify®, Bausch & Lomb’s branded brimonidine tartrate ophthalmic solution, against Somerset’s generic 0.025% formulation.
The outcome—a mutual walk-away with each party bearing its own costs—raises critical questions for ophthalmic patent infringement strategy: Was this a negotiated licensing resolution, a commercial pivot, or a recognition of litigation risk on both sides? While the record is silent on underlying terms, the procedural posture offers meaningful signals for patent attorneys, in-house IP counsel, and R&D leaders navigating the crowded ophthalmic drug patent landscape.
Case Overview
The Parties
⚖️ Plaintiff
Global ophthalmic products leader whose Lumify® brand (0.025% brimonidine tartrate) commands significant consumer and clinical recognition.
🛡️ Defendant
Generic pharmaceutical developer whose accused product is a generic brimonidine tartrate ophthalmic solution at 0.025%.
The Patents at Issue
Four U.S. patents formed the infringement foundation, protecting Lumify® through layered formulation, dosing, and method-of-use claims:
- • US8293742B2 — Ophthalmic solution formulations
- • US9259425B2 — Methods of reducing ocular redness
- • US11596600B2 — Improved ophthalmic compositions
- • US11833245B2 — Novel brimonidine tartrate solutions
Litigation Timeline & Procedural History
The case was filed on April 28, 2025, in the District of New Jersey (Case No. 3:25-cv-03395) and closed on January 12, 2026, marking a duration of 259 days. The rapid resolution, without a claim construction order or dispositive ruling, suggests early business discussions alongside litigation efforts. The dismissal was under Federal Rule of Civil Procedure 41(a)(1)(ii) and 41(c), indicating Somerset had asserted counterclaims (likely validity challenges).
Developing a generic pharmaceutical?
Check if your formulation or method of use might infringe existing patents.
The Verdict & Legal Analysis
Outcome
All claims, defenses, and counterclaims were dismissed without prejudice pursuant to joint stipulation, with each party bearing its own attorneys’ fees, costs, and expenses. No damages were awarded, and no injunctive relief was granted or denied on the merits.
Verdict Cause Analysis
The case was filed as a straightforward infringement action. The absence of any disclosed Markman ruling, expert report, or dispositive motion before dismissal indicates the merits were never adjudicated. Somerset’s likely counterclaims asserting invalidity (inferred from the Rule 41(c) dismissal) were also dismissed without prejudice, meaning no court ever validated or invalidated the four Bausch & Lomb patents.
Legal Significance
The “without prejudice” designation is legally significant: Bausch & Lomb retains the right to re-file infringement claims on any or all four patents should Somerset re-enter the market or modify its product, and Somerset’s invalidity counterclaims remain unresolved on the merits. These patents emerge from this litigation with their claims entirely intact and untested by judicial interpretation.
Drafting a pharmaceutical patent?
Learn from this case. Use AI to draft stronger formulation or method claims.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in ophthalmic pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all patents in the brimonidine tartrate space
- See which companies are most active in ophthalmic patents
- Understand claim construction patterns for formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical product.
- Input your product formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Low-concentration brimonidine formulations
4 Patents Asserted
Covering formulation & method of use
Method of Use Claims
Key to assessing infringement risk
✅ Key Takeaways
For Patent Attorneys & Litigators
A four-patent assertion stack creates multi-front pressure that often accelerates resolution before claim construction.
Search related case law →Rule 41(a)(1)(ii) stipulated dismissals preserve future enforcement rights—the without-prejudice posture is strategically distinct from covenant-not-to-sue agreements.
Explore precedents →District of New Jersey remains a premier venue for pharmaceutical patent enforcement.
View D.N.J. case trends →Counterclaim filing by defendants signals litigation seriousness and strengthens negotiating position.
Analyze defensive strategies →For IP Professionals
Monitor Somerset Therapeutics’ regulatory filings and product pipeline for signals of re-entry.
Track company IP activity →Multi-generational patent portfolios provide extended enforcement windows requiring continuous portfolio management.
Manage your patent portfolio →For R&D Leaders
Generic ophthalmic formulation development requires FTO analysis across composition, method-of-use, and dosing claim categories.
Start FTO analysis for my product →Early-stage resolution in this case does not signal patent weakness; it may signal commercial agreement, requiring independent technical risk assessment before market entry.
Assess market entry risks →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.